History and new insights into host defense against vaginal candidiasis

Trends in Microbiology

Volumn 12, Issue 5, 2004, Pages 220-227

  Fidel Jr , Paul L ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA ALBICANS; CELLULAR IMMUNITY; DISEASE PREDISPOSITION; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION SENSITIVITY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTECTION; REVIEW; VAGINA CANDIDIASIS; VAGINA EPITHELIUM; VAGINA MUCOSA; VAGINA SECRETION; VAGINITIS;

ANIMALS; CANDIDIASIS, VULVOVAGINAL; DISEASE MODELS, ANIMAL; FEMALE; HISTORY, 20TH CENTURY; HUMANS; IMMUNITY, NATURAL; MODELS, IMMUNOLOGICAL; NEUTROPHILS; RECURRENCE;

ANIMALIA; CANDIDA; CANDIDA ALBICANS;

EID: 2042504392     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2004.03.006     Document Type: Review

References (70)

1. Sobel J.D., et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am. J. Obstet. Gynecol. 178:1998;203-211
2. Calderone R.A. Candida and Candidiasis. 2002;ASM Press
3. Sobel J.D. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin. Infect. Dis. 14:1992;S148-S153
4. Vanden-Bossche H., et al. Characterization of an azole-resistant candida glabrata isolate. Antimicrob. Agents Chemother. 36:1992;2602-2610
5. Klein R.S., et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:1984;354-357
6. Clift R.A. Candidiasis in the transplant patient. Am. J. Med. 77:(Suppl. 4D):1984;34-38
7. Samaranayake L.P. Oral mycoses in HIV infection. Oral Surg. Oral Med. Oral Pathol. 73:1992;171-180
8. Romani L., et al. Biological role of Th cell subsets in candidiasis. Romagnani S. Th1 and Th2 Cells in Health and Disease. 1996;114-137 Karger, Farmington, CT
9. Mathews H.L., Witek-Janusek L. Host defense against oral, esophageal, and gastrointestinal candidiasis. Carderone R.A. Candida and Candidiasis. 2002;179-192 ASM Press
10. Sohnle P.G., et al. Immunology of cutaneous candidiasis. Calderone R. Candida and Candidiasis. 2002;211-221 ASM Press
11. Fidel P.L. Jr, Sobel J.D. The role of cell-mediated immunity in candidiasis. Trends Microbiol. 2:1994;202-206
12. Fong I.W., et al. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am. J. Obstet. Gynecol. 166:1992;887-890
13. Hobbs J.R., et al. Immunological aspects of candidal vaginitis. Proc. R. Soc. Med. 70:1977;11-14
14. Mendling W., Koldovsky U. Investigations by cell-mediated immunologic tests and therapeutic trials with thymopentin in vaginal mycoses. Infect. Dis. Obstet. Gynecol. 4:1996;225-231
15. Fidel P.L. Jr, et al. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis (RVVC). J. Infect. Dis. 168:1993;1458-1465
16. Nawrot U., et al. The study of cell-mediated immune response in recurrent vulvovaginal candidiasis. FEMS Immunol. Med. Microbiol. 29:2000;89-94
17. Corrigan E.M., et al. Cellular immunity in recurrent vulvovaginal candidiasis. Clin. Exp. Immunol. 111:1998;574-578
18. Piccinni M.-P., et al. Type 1 T helper cells specific for Candida albicans antigens in peripheral blood and vaginal mucosa of women with recurrent vaginal candidiasis. J. Infect. Dis. 186:2002;87-93
19. Cu-Uvin S., et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-serpositive and high-risk HIV-seronegative women. Clin. Infect. Dis. 29:1999;1145-1150
20. White M.H. Is vulvovaginal candidiasis an AIDS-related illness. Clin. Infect. Dis. 22:(Suppl. 2):1996;S124-S127
21. Leigh J.E., et al. Candida-specific systemic cell-mediated immune reactivities in HIV-infected persons with and without mucosal candidiaisis. J. Infect. Dis. 183:2001;277-285
22. Rigg D., et al. Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy. Am. J. Obstet. Gynecol. 162:1990;332-336
23. Witkin S.S. Immunologic factors influencing susceptibility to recurrent candidal vaginitis. Clin. Obstet. Gynecol. 34:1991;662-668
24. Fidel P.L. Jr, et al. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: Evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J. Infect. Dis. 176:1997;728-739
25. Witkin S.S., et al. Effect of Candida albicans plus histamine on prostaglandin E2 production by peripheral blood mononuclear cells from healthy women and women with recurrent candidal vaginitis. J. Infect. Dis. 164:1991;396-399
26. Mathur S., et al. Humoral immunity in vaginal candidiasis. Infect. Immun. 15:1977;287-294
27. Kirkpatrick C.H., et al. Chronic mucocutaneous candidiasis: model building in cellular immunity. Ann. Intern. Med. 74:1971;955-978
28. Fidel P.L. Jr. Distinct protective host defenses against oral and vaginal candidiasis. Med. Mycol. 40:2002;359-375
29. Black C.A., et al. Increased severity of Candida vaginitis in BALB/c nu/nu mice versus the parent strain is not abrogated by adoptive transfer of T cell enriched lymphocytes. J. Reprod. Immunol. 45:1999;1-18
30. Cassone A., et al. Rats clearing a vaginal infection by Candida albicans aquire specific, antibody-mediated resistance to vaginal infection. Infect. Immun. 63:1995;2619-2624
31. De Bernardis F., et al. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65:1997;3399-3405
32. Wozniak K.L., et al. Candida-specific antibodies during experimental vaginal candidiasis in mice. Infect. Immun. 70:2002;5790-5799
33. Fidel P.L. Jr, et al. Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect. Immun. 67:1999;3135-3140
34. Taylor B.N., et al. Local Th1/Th2 cytokine production during experimental vaginal candidiasis. Med. Mycol. 38:2000;419-431
35. Saavedra M., et al. Local production of chemokines during experimental vaginal candidiasis. Infect. Immun. 67:1999;5820-5829
36. Fidel P.L. Jr, et al. T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect. Immun. 64:1996;3793-3799
37. Nandi D., Allison J.P. Phenotypic analysis and gamma/delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J. Immunol. 147:1991;1773-1778
38. + αβ T cells of the murine female genital tract: a phenotypically distinct T cell lineage that rapidly proliferates in response to systemic T cell activation stimuli. Int. Immunol. 7:1995;1763-1769
39. Wormley F.L. Jr, et al. Resistance of TCR δ-chain knock-out mice to experimental Candida vaginitis. Infect. Immun. 69:2001;7162-7164
40. Wormley F.L. Jr, et al. Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis. Infect. Immun. 69:2001;5072-5079
41. Santoni G., et al. Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors. Infect. Immun. 70:2002;4791-4797
42. Mulero-Marchese R.D., et al. Strain-dependent migration of lymphocytes to the vaginal mucosa after peripheral immunization. Immunogenetics. 49:1999;973-980
43. Black C.A., et al. Major histocompatibility haplotype does not impact the course of experimentally induced murine vaginal candidiasis. Lab. Anim. Sci. 49:1999;668-672
44. Fidel P.L. Jr, et al. Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections. Infect. Immun. 63:1995;4191-4194
45. Steele C., et al. Differential susceptibility to experimental vaginal candidiasis in macaques. J. Infect. Dis. 180:1999;802-810
46. Mulero-Marchese R.D., et al. Genetic basis for protection against experimental vaginal candidiasis by peripheral immunization. J. Infect. Dis. 178:1998;227-234
47. Calderon L., et al. Genetic susceptibility to vaginal candidiasis. Med. Mycol. 41:2003;143-147
48. + T cells. Am. J. Reprod. Immunol. 45:2001;200-204
49. Hladik F., et al. Coexpression of CCR5 and IL-2 in human genital but not blood cells: implications for the ontogeny of the CCR5+Th1 phenotype. J. Immunol. 163:1999;2306-2313
50. Fidel P.L. Jr, et al. Local immune responsiveness following intravaginal challenge with Candida antigen in adult women at different stages of the menstrual cycle. Med. Mycol. 41:2003;97-109
51. Giraldo P.C., et al. Circulating heat shock proteins in women with a history of recurrent vulvovaginitis. Infect. Dis. Obstet. Gynecol. 7:1999;128-132
52. Chaim W., et al. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. J. Infect. Dis. 176:1997;828-830
53. Babula O., et al. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin. Infect. Dis. 37:2003;733-737
54. Black C.A., et al. Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect. Immun. 66:1998;1273-1275
55. Fulurija A., et al. Neutrophil depletion increases susceptibility to systemic and vaginal candidiasis in mice, and reveals differences between brain and kidney in mechanisms of host resistance. Microbiology. 142:1996;3487-3496
56. Carlsten H., et al. Analysis of the genetic encoding of oestradiol suppression of delayed-type hypersensitivity in (NZB x NZW) F1 mice. Immunology. 73:1991;186-190
57. Sonoda Y., et al. Physiologic regulation of postovulatory neutrophil migration into vagina in mice by a C-X-C chemokine. J. Immunol. 160:1998;6159-6165
58. Parr M.B., Parr E.L. Langerhans cells and T lymphocyte subsets in the murine vagina and cervix. Biol. Reprod. 44:1991;491-498
59. Steele C., et al. Growth inhibition of Candida albicans by vaginal cells from naive mice. Med. Mycol. 37:1999;251-260
60. Barousse M.M., et al. Growth Inhibition of Candida albicans by human vaginal epithelial cells. J. Infect. Dis. 184:2001;1489-1493
61. Nomanbhoy F., et al. Vaginal and oral epithelial cell anti-Candida activity. Infect. Immun. 70:2002;7081-7088
62. Steele C., et al. Growth inhibition of Candida by human oral epithelial cells. J. Infect. Dis. 182:2000;1479-1485
63. Steele C., et al. Potential role for a carbohydrate moiety in anti-Candida activity of human oral epithelial cells. Infect. Immun. 69:2001;7091-7099
64. Mardh P.A., et al. Facts and myths on recurrent vulvovaginal candiosis - a review on epidemiology, clinical manifestations, diagnosis, pathogenesis, and therapy. Int. J. STD AIDS. 13:2002;522-539
65. Barousse, M., et al. Vaginal yeast colonization, prevalence of vaginitis, and associated local immunity in adolescents. Sex. Transm. Infect. (in press).
66. Cohen M.S., et al. Human experimentation with Neissaria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development. J. Infect. Dis. 169:1994;532-537
67. Al-Tawfig J.A., et al. Experimental infection of human volunteers with Haemophilus decreyi does not confer protection against subsequent challenge. J. Infect. Dis. 179:1999;1283-1287
68. Fidel, P.L., Jr, et al. A live intravaginal Candida challenge in humans reveals new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect. Immun. (in press).
69. Han Y., et al. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect. Immun. 66:1998;5771-5776
70. Magliani W., et al. Therapeutic potential of antiidiotype single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15:1997;155-158